TAT for Enzyme/Protein Delivery to Restore or Destroy Cell Activity in Human Diseases

Lichtenstein, Michal; Zabit, Samar; Hauser, Noa; Farouz, Sarah; Melloul, Orly; Hirbawi, Joud; Lorberboum-Galski, Haya

doi:10.3390/life11090924

Cited by 14 publications

(8 citation statements)

References 127 publications

(171 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TAT and TAT‐modified drugs can be internalized by cells and tissues rapidly and efficiently while retaining their biological activity (Vivès et al, 1997). In addition, many studies have shown that TAT and TAT‐modified drugs can cross the BBB and are therefore useful for the delivery of TAT protein‐modified drugs to the brain (Lichtenstein et al, 2021). A group led by Takanori Kanazawa has been working on the development of TAT‐modified polyethylene glycol‐ b ‐poly(ε‐caprolactone) (PEG‐PCL) micelles for the intranasal treatment of various brain diseases since 2012, and they have intensively studied the brain distribution and metabolic behavior of each system loaded with small molecules and nucleic acids (Table 3).…”

Section: Transcytosis In the Nose‐to‐brain Pathwaymentioning

confidence: 99%

Nose‐to‐brain delivery of nanotherapeutics: Transport mechanisms and applications

Xu,

Duan,

Wang

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

The blood–brain barrier presents a key limitation to the administration of therapeutic molecules for the treatment of brain disease. While drugs administered orally or intravenously must cross this barrier to reach brain targets, the unique anatomical structure of the olfactory system provides a route to deliver drugs directly to the brain. Entering the brain via receptor, carrier, and adsorption‐mediated transcytosis in the nasal olfactory and trigeminal regions has the potential to increase drug delivery. In this review, we introduce the physiological and anatomical structures of the nasal cavity, and summarize the possible modes of transport and the relevant receptors and carriers in the nose‐to‐brain pathway. Additionally, we provide examples of nanotherapeutics developed for intranasal drug delivery to the brain. Further development of nanoparticles that can be applied to intranasal delivery systems promises to improve drug efficacy and reduce drug resistance and adverse effects by increasing molecular access to the brain.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease

show abstract

Section: Transcytosis In the Nose‐to‐brain Pathwaymentioning

confidence: 99%

Nose‐to‐brain delivery of nanotherapeutics: Transport mechanisms and applications

Xu,

Duan,

Wang

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…[112]. Successful protein transport to the brain has been accomplished after protein-to-TAT peptide conjugation [113].…”

Section: Peptidesmentioning

confidence: 99%

Solid Lipid Nanoparticles: A Review on Different Techniques and Approaches to Treat Breast Cancer

GAJBHIYE¹,

Patil²

2023

Int J App Pharm

View full text Add to dashboard Cite

Breast cancer, the most common malignancy among women, is also the second-leading cause of cancer deaths all over the world. As commonly used chemotherapy drugs, which are given systematically, causes toxicity not only to cancerous cells but also to proliferating normal cells. Similarly, drug resistance leads to drastic side effects and treatment failure. Thus arises the need for improving the therapeutic index of anticancer drugs. Owing to these failures, nanotechnology holds significant promises. Using keywords like multi-drug resistance, effective targeting, therapeutics, intracellular pathways, efficacy, and breast cancer, references were looked up from specialised databases including Elsevier, Pubmed, and Cambridge from the year 1994 to 2023. This review was supplemented by a few references from Springer Nature and pertinent data from an online source. Along with online articles from Medscape, StatPearls, and The Lancet Respiratory Medicine, it was excellent. Supported literature was used to overcome these challenges; therapeutic drugs are encapsulated in nanoparticles. Concurrently, solid lipid nanoparticles (SLN), with their few merits, like enhancing the therapeutic profile, overcoming multidrug resistance, providing a targeted approach, and serving as a controlled release, have gained the attention of researchers. SLNs confine significant promises, overcome these challenges, and help to possibly deliver the drug to a specific part of the body, particular organ, or tissue by an actively or passively targeted delivery system, which will be beneficial in the diagnosis and treatment of breast cancer. The objective of this article is to highlight the factors that influence the targeted drug delivery system and resultant bioavailability and also provide updates on recent research and various approaches used for breast drug delivery systems.

show abstract

“…CPPs are mainly small and cationic peptides consisting of 5-30 amino acids that are able to move through the lipid bilayer. Because of their ability to carry biologically active cargos, such as proteins, 21,22 nucleic F I G U R E 1 Representation of membrane interaction of (a) fusion peptides, (b) antimicrobial peptides, and (c) cell-penetrating peptides acids, 23 or nanoparticles 24,25 across the membrane, they are also referred to as protein transduction domains (PTDs). The first CPPs to be discovered were the HIV-1 TAT protein in 1988 26 and penetratin in 1994.…”

Section: Cell-penetrating Peptidesmentioning

confidence: 99%

Artificial peptides to induce membrane denaturation and disruption and modulate membrane composition and fusion

Lāce

Cotroneo

Hesselbarth

et al. 2022

Journal of Peptide Science

View full text Add to dashboard Cite

Membranes consisting of phospholipid bilayers are an essential constituent of eukaryotic cells and their compartments. The alteration of their composition, structure, and morphology plays an important role in modulating physiological processes, such as transport of molecules, cell migration, or signaling, but it can also lead to lethal effects. The three main classes of membrane‐active peptides that are responsible for inducing such alterations are cell‐penetrating peptides (CPPs), antimicrobial peptides (AMPs), and fusion peptides (FPs). These peptides are able to interact with lipid bilayers in highly specific and tightly regulated manners. They can either penetrate the membrane, inducing nondestructive, transient alterations, or disrupt, permeabilize, or translocate through it, or induce membrane fusion by generating attractive forces between two bilayers. Because of these properties, membrane‐active peptides have attracted the attention of the pharmaceutical industry, and naturally occurring bioactive structures have been used as a platform for synthetic modification and the development of artificial analogs with optimized therapeutic properties to transport biologically active cargos or serve as novel antimicrobial agents. In this review, we focus on synthetic membrane interacting peptides with bioactivity comparable with their natural counterparts and describe their mechanism of action.

show abstract

TAT for Enzyme/Protein Delivery to Restore or Destroy Cell Activity in Human Diseases

Cited by 14 publications

References 127 publications

Nose‐to‐brain delivery of nanotherapeutics: Transport mechanisms and applications

Nose‐to‐brain delivery of nanotherapeutics: Transport mechanisms and applications

Solid Lipid Nanoparticles: A Review on Different Techniques and Approaches to Treat Breast Cancer

Artificial peptides to induce membrane denaturation and disruption and modulate membrane composition and fusion

Contact Info

Product

Resources

About